Unum Therapeutics Inc UMRX shares are trading higher on Tuesday after Wedbush upgraded the stock from Neutral to Overweight and raised its target price from $1 to $4.
Unum Therapeutics Inc is a U.S. based clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer.
Unum Therapeutics Inc shares were trading up 4.09% at $2.29 at time of publication on Tuesday. The stock has a 52-week high of $3.40 and a 52-week low of 30 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
